Cyclo Therapeutics Q2 EPS $(0.21) Misses $(0.16) Estimate, Sales $123.10K Miss $267.50K Estimate
Portfolio Pulse from Benzinga Newsdesk
Cyclo Therapeutics (NASDAQ:CYTH) reported Q2 earnings per share (EPS) of $(0.21), missing the analyst estimate of $(0.16) by 31.25%. Sales were $123.10K, missing the estimate of $267.50K by 53.98%. Despite the misses, EPS improved by 36.36% and sales increased by 5.11% year-over-year.
August 15, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cyclo Therapeutics reported Q2 EPS of $(0.21), missing the analyst estimate of $(0.16) by 31.25%. Sales were $123.10K, missing the estimate of $267.50K by 53.98%. Despite the misses, EPS improved by 36.36% and sales increased by 5.11% year-over-year.
The significant misses on both EPS and sales estimates are likely to negatively impact the stock price in the short term. However, the year-over-year improvements in EPS and sales may provide some support, but the immediate reaction is expected to be negative.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100